Asset Details
Do you wish to reserve the book?
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor
Do you wish to request the book?
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor
2025
Overview
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used for the treatment of type 2 diabetes mellitus. Recently, their association with drug-induced bullous pemphigoid (BP) has attracted increasing attention. In this report, we present a case of an 84-year-old woman who developed BP after COVID-19 infection while taking a DPP-4 inhibitor. The temporal relationship between drug administration, viral infection, and onset of autoimmune disease indicates a possible interaction between COVID-19-induced immune dysregulation and DPP-4 inhibition. The coexistence of these factors may increase the risk of developing BP in older patients with diabetes, which warrants careful monitoring.
Publisher
Cureus
Subject
